22-28695252-G-C
Variant summary
Our verdict is Likely benign. Variant got -3 ACMG points: 0P and 3B. BP4_ModerateBP6
The NM_007194.4(CHEK2):c.1260-10C>G variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000714 in 1,456,854 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_007194.4 intron
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -3 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000592 AC: 9AN: 152122Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000603 AC: 15AN: 248898Hom.: 1 AF XY: 0.0000445 AC XY: 6AN XY: 134704
GnomAD4 exome AF: 0.0000728 AC: 95AN: 1304732Hom.: 0 Cov.: 19 AF XY: 0.0000821 AC XY: 54AN XY: 657398
GnomAD4 genome AF: 0.0000592 AC: 9AN: 152122Hom.: 0 Cov.: 32 AF XY: 0.0000269 AC XY: 2AN XY: 74296
ClinVar
Submissions by phenotype
not provided Uncertain:1Benign:5
- -
- -
The CHEK2 c.1260-10C>G variant has been reported in the published literature in an individual with breast cancer (PMID: 25186627 (2015)). The frequency of this variant in the general population, 0.00026 (13/50354 chromosomes (Genome Aggregation Database, http://gnomad.broadinstitute.org)), is uninformative in the assessment of its pathogenicity. Analysis of this variant using software algorithms for the prediction of the effect of nucleotide changes on CHEK2 mRNA splicing yielded inconclusive findings. Based on the available information, we are unable to determine the clinical significance of this variant. -
- -
- -
- -
not specified Benign:4
Variant summary: The CHEK2 c.1260-10C>G variant involves the alteration of a non-conserved intronic nucleotide. One in silico tool predicts a damaging outcome for this variant. 5/5 splice prediction tools predict no significant impact on normal splicing. However, these predictions have yet to be confirmed by functional studies. This variant was found in 6/110696 control chromosomes (1 homozygote) in ExAC and 17/275124 control chromosomes in gnomAD (1 homozygote), predominantly observed in the European (Non-Finnish) subpopulation at frequency of 0.0001 (6/59812 in ExAC) and 0.0001355 (17/125452 in genomAD). These frequency are about 4 ~ 5 times the estimated maximal expected allele frequency of a pathogenic CHEK2 variant (0.0000284), suggesting this is likely a benign polymorphism found primarily in the populations of European (Non-Finnish) origin. This variant has been reported in one BrC patient without strong evidence for causality. In addition, multiple clinical diagnostic laboratories/reputable databases classified this variant as benign/likely benign. Taken together, this variant is classified as benign. -
This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. -
- -
- -
Hereditary cancer-predisposing syndrome Benign:2
- -
- -
Breast and/or ovarian cancer Benign:1
- -
Familial cancer of breast Benign:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at